Open AccessInfluence of KDR Genetic Variation on the Effectiveness and Safety of Bevacizumab in the First-Line Treatment for Patients with Advanced Colorectal Cancer
Author(s) -
Fei Wang,
Gang Liu
Publication year - 2022
Publication title -
international journal of general medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.722
H-Index - 36
ISSN - 1178-7074
DOI - 10.2147/ijgm.s362366
Subject(s) - bevacizumab , medicine , genotype , genotyping , colorectal cancer , odds ratio , gastroenterology , oncology , vascular endothelial growth factor , allele , cancer , chemotherapy , gene , vegf receptors , biology , genetics
Bevacizumab is usually considered a first-line anti-tumor therapy, which inhibits tumor growth by downregulating the vascular endothelial growth factor (VEGF) that further silences the activity of the kinase insert region receptor (KDR) gene. In the current study, we investigated the treatment response of bevacizumab in advanced colorectal cancer (CRC) patients bearing 889 C>T mutation in the KDR gene.